**Jushi Holdings Inc. to Acquire a Pennsylvania Grower-Processor Permit Holder;   
Reaffirms 2021 Revenue Guidance**

*Signs Definitive Binding Agreement to Purchase the Equity of a Grower-Processor in Pennsylvania;*

*Solidifies Jushi’s Position in One of the Most Attractive Medical Cannabis Markets in the Country.*

**BOCA RATON, Fla., June 22, 2020 –** [**Jushi Holdings Inc.**](https://www.jushico.com/) **(“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF)**, a globally-focused, multi-state cannabis and hemp operator, has reached a definitive binding agreement (the “Agreement”) to acquire 100% of the equity of Pennsylvania Medical Solutions, LLC (the “Permittee”), a Pennsylvania grower-processor owned by Vireo Health International, Inc. (“Vireo”) (CNSX: VREO; OTCQX: VREOF) (the “Proposed Acquisition”). The Permittee operates a 90,000 sq. ft. facility with approximately 45,000 sq. ft. of high-quality, indoor cultivation when construction is complete. The Permittee’s property can further accommodate an additional 25,000 sq. ft. of indoor cultivation bringing the total to 70,000 sq. ft. The Proposed Acquisition will solidify Jushi’s leadership position in Pennsylvania by adding equity ownership of Permittee, with its large-scale, high-quality, indoor cannabis cultivation and processing capabilities, to its other subsidiaries’ collective rights to operate up to 15 dispensaries.1

**Proposed Equity Acquisition Highlights:**

* The facility produces high-quality, indoor grown flower, extracts, and concentrates;
* An expansion currently underway is expected to be completed by mid-2020;
  + Increasing indoor cultivation from 20,000 sq. ft. to 45,000 sq. ft. of cultivation;2
  + Supplementing current CO2 extraction with a new Class I, Division 1 ethanol extraction room;
* Post-expansion, the facility is expected to produce between 800 to 1,000 lbs. of dried flower per month;
* The facility is expected to supply the Company’s subsidiaries, and other licensed retail facilities.

“This acquisition allows Jushi to expand its presence in one of the most attractive medical cannabis markets in the country”, said Jim Cacioppo, Chairman and Chief Executive Officer of Jushi. “Upon completion Jushi will be able to provide high-quality, indoor flower and concentrates to our Pennsylvania patients who continue to experience constrained supply and high prices. Furthermore, we will be well-positioned to support an increase in demand and maintain the ability to further scale up the facility if required.”

Under the terms of the Agreement, Jushi will pay Vireo (subject to purchase price adjustments) US$16.3 million in cash, a US$3.8 million seller note,3 and assume a US$17 million facility associated with a long-term lease obligation. No equity will be issued in connection with this acquisition. Jushi intends to fund the cash portion of the Agreement with the proceeds from the debt financing, which Jushi announced concurrently with this announcement. The parties anticipate closing the Agreement by the end of August 2020.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  
 Seven stores are currently operational. Includes three additional stores related to an equity investment under definitive agreement  
2 Preliminary expansion capacity, subject to completion of additional due diligence

3 8% unsecured seller note, four-year maturity, with all principal and interest due at maturity

As part of the Agreement, at closing, Jushi will have an assignable purchase option (“Option”) to acquire 100% of the equity of Pennsylvania Dispensary Solutions, LLC (“PADS”), a Pennsylvania medical marijuana dispensary permittee in the Commonwealth’s Northeast region. PADS currently operates two medical marijuana dispensaries in Scranton and Bethlehem, with the right to operate one additional dispensary in the region. The Option expires 18 months from closing of the Agreement, and is subject to certain closing conditions, including approvals from all applicable regulatory authorities.  
  
Since inception, [Pennsylvania's](https://www.health.pa.gov/topics/Documents/Programs/Medical%20Marijuana/1113Jones-MMAB.pdf) medical cannabis total marketplace has had a total of US$524 million in sales — US$215 million in purchases made by dispensaries from grower-processors and US$309 million made by patients and caregivers at licensed dispensaries. Currently, there are roughly 80 operational Pennsylvania dispensaries and 297,317 medical marijuana patients and 29,040 caregivers registered in the Program, according to the Pennsylvania Department of Health.

The Proposed Acquisition is subject to certain closing conditions, including approvals from regulatory authorities. There can be no assurance that the transaction will be completed.

Jushi is reaffirming its 2021 revenue guidance of $200 to $250 million and will provide more detail at the expected close of the Proposed Acquisition.

**About Jushi Holdings Inc.**We are a globally focused cannabis and hemp company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis and hemp-derived assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis and hemp ecosystem. For more information, please visit <https://www.jushico.com/> or [on Facebook, Twitter](https://twitter.com/wearejushi?lang=en), or [LinkedIn](https://www.linkedin.com/company/jushi-inc).

**About Vireo Health International, Inc.**

Vireo Health International, Inc. is a physician-led cannabis company focused on building long-term, sustainable value by bringing the best of medicine, science, and engineering to the cannabis industry. With operations strategically located in early-stage, limited-license medical markets, Vireo manufactures pharmaceutical-grade cannabis products in environmentally-friendly greenhouses and distributes its products through its growing network of Green Goods™ retail dispensaries and hundreds of third-party locations. Its current core medical markets of New York, Minnesota, Pennsylvania, Arizona, New Mexico, and Maryland all have the potential to enact adult-use legalization in the next three to 24 months, and two additional markets in Puerto Rico and Massachusetts also have potential for commercialization. Combined with its teams' focus on driving scientific innovation within the industry and securing meaningful intellectual property, Vireo believes it is well positioned to become a global market leader in the cannabis industry. Today, eight of its 10 markets are operational with 13 of its 32 total retail dispensary licenses open for business. For more information about the company, please visit [www.vireohealth.com](http://www.vireohealth.com).

**Forward-Looking Information and Statements**This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or may contain statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “will continue,” “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, information concerning the expectations regarding Jushi, or the ability of Jushi to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability of Jushi to successfully achieve business objectives, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; and compliance with extensive government regulation, as well as other risks and uncertainties which are more fully described in the Company’s Annual Information Statement dated June 1, 2020 and other filings with securities and regulatory authorities which are available at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

**Investor Relations Contact:**Michael Perlman  
Executive Vice President of Investor Relations and Treasury  
561-453-1308  
Investors@jushico.com

**Media Contact:**Ellen Mellody  
MATTIO Communications  
570-209-2947  
Ellen@Mattio.com

###